UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

The Lancet (British edition), 2016-04, Vol.387 (10027), p.1551-1560

2016

Volltextzugriff (PDF)

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

British journal of haematology, 2012-09, Vol.158 (6), p.727-738

2012

Volltextzugriff (PDF)

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2019-01, Vol.19 (1), p.29-34

2019

Volltextzugriff (PDF)

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

Blood, 2011-07, Vol.118 (4), p.865-873

2011

Volltextzugriff (PDF)

Development of the Histoculture Drug Response Assay (HDRA)

Methods in molecular biology (Clifton, N.J.), 2018-01, Vol.1760, p.39

2018

Volltextzugriff (PDF)

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

Blood, 2014-10, Vol.124 (16), p.2498-2506

2014

Volltextzugriff (PDF)

Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Journal of clinical oncology, 2006-02, Vol.24 (6), p.937-944

2006

Volltextzugriff (PDF)

The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents

Clinical cancer research, 2003-03, Vol.9 (3), p.1136-1144

2003

Volltextzugriff (PDF)

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

Blood, 2009-08, Vol.114 (8), p.1489-1497

2009

Volltextzugriff (PDF)

Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution

The Lancet (British edition), 2000-05, Vol.355 (9218), p.1875-1881

2000

Volltextzugriff (PDF)

Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients

Bone marrow transplantation (Basingstoke), 2020-06, Vol.55 (6), p.1059-1067

2020

Volltextzugriff (PDF)

An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma

American journal of hematology, 2009-10, Vol.84 (10), p.650-656

2009

Volltextzugriff (PDF)

Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4239-4247

2003

Volltextzugriff (PDF)

Optimizing Care: Discontinuing Medications Prior to Daratumumab and Hyaluronidase-Fihj Subcutaneous Injection (OMIT)

Blood, 2020-11, Vol.136 (Supplement 1), p.22-23

2020

Volltextzugriff (PDF)

Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group

Journal of clinical oncology, 2000-03, Vol.18 (6), p.1351-1359

2000

Volltextzugriff (PDF)

Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial

Journal of clinical oncology, 2001-09, Vol.19 (17), p.3771-3779

2001

Volltextzugriff (PDF)

A Phase I Dose-ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases

Clinical cancer research, 2001-03, Vol.7 (3), p.478-485

2001

Volltextzugriff (PDF)

Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

British journal of haematology, 2010-02, Vol.148 (4), p.562-568

2010

Volltextzugriff (PDF)

Salvage Autologous Peripheral Blood Stem Cell Transplantation after the Development of tMDS or AML in Multiple Myeloma Patients

Blood, 2023-11, Vol.142 (Supplement 1), p.7079-7079

2023

Volltextzugriff (PDF)

Reverse Autologous Peripheral Blood Stem Cell Transplantation after Allogeneic Transplantation to Restore Immune Function and Pancytopenia

Blood, 2023-11, Vol.142 (Supplement 1), p.7057-7057

2023

Volltextzugriff (PDF)

Scalp Cooling to Prevent Hair Loss in Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation

Blood, 2023-11, Vol.142 (Supplement 1), p.7080-7080

2023

Volltextzugriff (PDF)

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

Annals of hematology, 2008-08, Vol.87 (8), p.623-631

2008

Volltextzugriff (PDF)

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-08, Vol.375 (8), p.754-766

2016

Volltextzugriff (PDF)

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

Leukemia, 2010-06, Vol.24 (6), p.1121-1127

2010

Volltextzugriff (PDF)

IMWG consensus on risk stratification in multiple myeloma

Leukemia, 2014-02, Vol.28 (2), p.269-277

2014

Volltextzugriff (PDF)

1 – 25 von 171

Suche als RSS-Feed

Aktive Filter

KollektionJSTOR

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(154)
Mit Volltextzugriff
(148)

Publikationsform

Artikel
(168)
Bücher
(2)
Berichte
(1)

Sprache

Englisch
(171)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Humans
(81)
Science & Technology
(80)
Life Sciences & Biomedicine
(79)
Biological And Medical Sciences
(45)
Hematology
(43)
Medical Sciences
(41)
Female
(39)
Male
(38)
Middle Aged
(37)
Oncology
(36)
Aged
(34)
Adult
(32)
Multiple Myeloma - Drug Therapy
(32)
Multiple Myeloma
(30)
Hematologic And Hematopoietic Diseases
(22)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(20)
Aged, 80 And Over
(19)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Immunodeficiencies. Immunoglobulinopathies
(19)
Immunoglobulinopathies
(19)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

Development of the Histoculture Drug Response Assay (HDRA)

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution

Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients

An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma

Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis

Optimizing Care: Discontinuing Medications Prior to Daratumumab and Hyaluronidase-Fihj Subcutaneous Injection (OMIT)

Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group

Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial

A Phase I Dose-ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases

Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

Salvage Autologous Peripheral Blood Stem Cell Transplantation after the Development of tMDS or AML in Multiple Myeloma Patients

Reverse Autologous Peripheral Blood Stem Cell Transplantation after Allogeneic Transplantation to Restore Immune Function and Pancytopenia

Scalp Cooling to Prevent Hair Loss in Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

IMWG consensus on risk stratification in multiple myeloma

Aktive Filter

Suchergebnisse filtern